Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, AIDS-Related 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Hodgkin Disease 1Breast Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Rituximab 32Cyclophosphamide 28Lenalidomide 19Prednisone 16Doxorubicin 16Vincristine 14Etoposide 11CT-P10 11Gemcitabine 9polatuzumab vedotin 8Oxaliplatin 7ibrutinib 6glofitamab 6fludarabine 6acalabrutinib 6Magnetic Resonance Spectroscopy 6Ifosfamide 6Carboplatin 6tafasitamab 5prednylidene 5pembrolizumab 5obinutuzumab 5deltacortene 5Specimen Handling 5R-CHOP protocol 5Nivolumab 5Biopsy 5venetoclax 4fludarabine phosphate 4selinexor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Large B-Cell, Diffuse × pegylated granulocyte colony-stimulating factor × Clear all
NCT04323956 2026-02-02

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Mayo Clinic

Phase 1 Active not recruiting
50 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡